NC
SRPT icon

Nexthera Capital’s Sarepta Therapeutics SRPT Stock Holding History

Nexthera Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$7.65M Buy
50,317
+29,047
+137% +$3.53M 6.37% 5
2019
Q1 		$2.54M Buy
+21,270
New +$2.73M 3.08% 12

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital's SRPT Position: Q2 2019 in Review

Nexthera Capital increased its Sarepta Therapeutics (SRPT) stake by 137% in Q2 2019, buying an estimated $3.53M and bringing the position to 50,317 shares worth $7.65M. The position accounts for 6.37% of the portfolio, ranked #5.

Nexthera Capital first reported a position in SRPT in Q1 2019 and has held it in 2 quarters since. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Nexthera Capital held 50,317 shares of Sarepta Therapeutics worth $7.65M as of Q2 2019.
  • Nexthera Capital bought 29,047 Sarepta Therapeutics shares in Q2 2019, an estimated $3.53M.
  • Sarepta Therapeutics made up 6.37% of Nexthera Capital's portfolio in Q2 2019, its #5 holding.
  • Nexthera Capital first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 2 quarters since.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.